Skeletal Complications and Mortality in Thyroid Cancer: A Population-Based Study

Choksi, Palak; Papaleontiou, Maria; Guo, Cui; Worden, Francis P.; Banerjee, Mousumi; Haymart, Megan R.

doi:10.1210/jc.2016-3906

Cited by 62 publications

(67 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in our study, although 39.5% of the patients had a FTC, we did not find different rates in the occurrence of SRE according to histological type. The high percentage of patients with SRE in our series may be the result of a larger number of patients submitted to radiotherapy than in other studies [11, 13]. In addition, in our cohort, the presence of a SRE was not associated with a significant increase in specific mortality at 5- or 10-years, in comparison with patients without SRE which is not consistent with previous reports [11].…”

Section: Discussioncontrasting

confidence: 90%

“…The number of patients that developed SRE was high (76.7%), which is similar to the findings of Farooki et al [7], 78%, but much higher than the results of Choksi et al [11] that only report SRE in 32% of their cases. The authors of this last study argue that their different results, as compared to Farooki et al, may be due to a higher percentage of patients with FTC in this cohort which was 34 versus 8% in their series.…”

Section: Discussionsupporting

confidence: 87%

“…In common with other series, the study population was mainly composed of females and had a median age of > 50 years [11, 13]. Consistent with a recently published systematic review, the patients presented predominantly multiple bone involvement with spine preference [14].…”

Section: Discussionsupporting

confidence: 57%

“…The high percentage of patients with SRE in our series may be the result of a larger number of patients submitted to radiotherapy than in other studies [11, 13]. In addition, in our cohort, the presence of a SRE was not associated with a significant increase in specific mortality at 5- or 10-years, in comparison with patients without SRE which is not consistent with previous reports [11]. Regarding treatment options, we could not confirm, like others [18], the beneficial effects of bisphosphonates described by Vitale et al [19] , probably because the number of patients treated with these drugs in our series was very small.…”

Section: Discussionmentioning

confidence: 68%

See 3 more Smart Citations

Bone Metastases from Thyroid Carcinoma of Follicular Origin: A Single Institutional Experience

Matta-Coelho

Simões‐Pereira

Vilar³

et al. 2018

Eur Thyroid J

View full text Add to dashboard Cite

Background/Aims: Overall, 2–13% of patients with thyroid cancer develop bone metastases (BM). In addition to decreased survival, patients with BM may present skeletal-related events (SRE) that impair the quality of life. Our objectives were to characterize clinical features, treatment approaches, and outcomes of patients with thyroid cancer and BM. Material and Methods: We identified patients diagnosed with thyroid carcinoma of follicular origin and BM followed at the Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Lisbon, Portugal, from 1991 to 2017. SRE were defined as the need for bone irradiation, bone surgery, spinal cord compression, or pathologic fractures. Results: The final cohort consisted of 86 patients, with a median follow-up time of 54 months (IQR 22.8–82.8), mainly women (67.4%), and a median age of 64 years (IQR 53.6–71.2). BM was the initial presentation of thyroid cancer in 36.0% of the patients. Bone involvement was multiple in 59.3% of the cases. Papillary carcinoma was the most frequent histological type, present in 47.7% of the patients, of which 56.1% presented the follicular variant. SRE were found in 76.7% of the patients. The most frequent SRE was radiotherapy (66.3%). Treatment with bisphosphonates was initiated in 19.8% of the patients. The 5-year specific survival was 60%, whereas the 10-year specific survival decreased to 50%. There were no differences in 5- or 10-year specific survival regarding gender, the occurrence of SRE, or histological type. However, patients with initial radioiodine non-avid lesions had a lower 5- and 10-year specific survival (p = 0.002). Discussion: The high frequency of patients with SRE was notable. The follicular variant of papillary thyroid cancer was the variant most commonly associated with BM, reflecting a more similar behavior to follicular carcinoma than the classic variant.

show abstract

Section: Discussioncontrasting

confidence: 90%

Section: Discussionsupporting

confidence: 87%

Section: Discussionsupporting

confidence: 57%

Section: Discussionmentioning

confidence: 68%

See 2 more Smart Citations

Bone Metastases from Thyroid Carcinoma of Follicular Origin: A Single Institutional Experience

Matta-Coelho

Simões‐Pereira

Vilar³

et al. 2018

Eur Thyroid J

View full text Add to dashboard Cite

show abstract

“…pathological fractures, spinal cord compression, need for radiation (for pain or impending fracture) or surgery and hypercalcaemia. Up to 37% of TC patients experience SREs, and they are associated with poorer prognoses [84,85].…”

Section: Management Of Advanced/metastatic Diseasementioning

confidence: 99%

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

et al. 2019

View full text Add to dashboard Cite

Skeletal Complications

Via¹,

Iofin²,

Liu³

et al. 2022

Holland‐Frei Cancer Medicine

View full text Add to dashboard Cite

Overview The skeletal complications of cancer are highly prevalent. Bone metastases are present in approximately 70% of patients with cancer‐related deaths. Skeletal complications can present clinically as pain associated with bone metastases, pathologic fractures, or hypercalcemia. Additionally, several therapies for cancers may have deleterious effect on bone health such as aromatase inhibition in patients with breast cancer. The presence of skeletal metastases often indicates that cure from cancer unlikely. Goals of therapy may shift to palliation and to systemic control with possible prolonged survival. Surgical treatments, medical therapies, including antiresorptive agents, and/or radiation therapy should each be considered to achieve optimal care in patients with skeletal complications of cancer.

show abstract

Skeletal Complications and Mortality in Thyroid Cancer: A Population-Based Study

Abstract: Bone events in patients with thyroid cancer are a poor prognostic indicator. Patients with follicular and medullary thyroid cancers are at especially high risk for skeletal complications.

Cited by 62 publications

References 27 publications

Bone Metastases from Thyroid Carcinoma of Follicular Origin: A Single Institutional Experience

Bone Metastases from Thyroid Carcinoma of Follicular Origin: A Single Institutional Experience

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Skeletal Complications

Contact Info

Product

Resources

About